Nifty
:
25044.35
Sensex
:
82055.11
72.45 (0.29%)
158.32 (0.19%)
Nifty
Sensex
:
:
25044.35
82055.11
72.45 (0.29%)
158.32 (0.19%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
59/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
1683.10
24-Jun-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1691
  •  1703.7
  •  1674.6
  •  1684.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1352660
  •  2289290501.3
  •  1830.95
  •  1199.3

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 47,463.35
  • 45.33
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 47,952.32
  • 0.15%
  • 5.36

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.18%
  • 12.32%
  • FII
  • DII
  • Others
  • 23.15%
  • 13.33%
  • 2.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.87
  • 2.11
  • -1.35

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.16
  • -6.78
  • -12.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.76
  • 30.71
  • 37.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.25
  • 13.70
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.66
  • 2.62
  • 3.06

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.45
  • 10.69
  • 12.35

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
-53.22
37.11
61.3
76.14
P/E Ratio
-31.63
45.35
27.46
22.11
Revenue
11635
13146
14825
16570
EBITDA
1244
2289
2836
3370
Net Income
-1502
1047
1733
2130
ROA
-8.9
6.9
13.5
16
P/B Ratio
2.07
5.37
4.53
3.81
ROE
-17.34
12.54
17.86
18.72
FCFF
-1663
-1726
1083
1717
FCFF Yield
-4.19
-4.35
2.73
4.32
Net Debt
-429
767
-917
-2114
BVPS
814.02
313.59
371.52
441.4

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
3,256.21
3,062.95
6.31%
3,387.55
2,506.70
35.14%
3,433.80
3,207.38
7.06%
3,244.19
3,036.07
6.85%
Expenses
2,695.18
2,558.61
5.34%
2,787.32
2,715.35
2.65%
2,831.88
2,745.09
3.16%
2,655.97
2,598.71
2.20%
EBITDA
561.03
504.34
11.24%
600.23
-208.65
-
601.91
462.28
30.20%
588.21
437.35
34.49%
EBIDTM
17.23%
16.47%
17.72%
-8.32%
17.53%
14.41%
18.13%
14.41%
Other Income
11.68
773.16
-98.49%
31.13
45.41
-31.45%
39.42
1.70
2,218.82%
31.49
19.72
59.69%
Interest
66.71
148.56
-55.10%
52.29
134.34
-61.08%
48.48
121.46
-60.09%
39.58
111.61
-64.54%
Depreciation
125.20
151.34
-17.27%
122.74
147.07
-16.54%
120.28
141.45
-14.97%
117.79
142.04
-17.07%
PBT
7.97
530.83
-98.50%
456.33
-521.38
-
472.57
-124.35
-
462.33
151.40
205.37%
Tax
3.59
1,769.47
-99.80%
108.30
-71.80
-
118.09
55.95
111.06%
122.10
113.72
7.37%
PAT
4.38
-1,238.65
-
348.03
-449.58
-
354.49
-180.30
-
340.24
37.68
802.97%
PATM
0.13%
-40.44%
10.27%
-17.94%
10.32%
-5.62%
10.49%
1.24%
EPS
0.16
-43.17
-
12.33
-12.45
-
12.55
-2.90
-
12.06
5.31
127.12%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
13,321.75
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
Net Sales Growth
12.77%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
 
Cost Of Goods Sold
4,353.35
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
Gross Profit
8,968.40
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
GP Margin
67.32%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
Total Expenditure
10,970.35
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
Power & Fuel Cost
-
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
120.47
109.11
% Of Sales
-
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
Employee Cost
-
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
% Of Sales
-
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
Manufacturing Exp.
-
813.30
633.51
784.63
638.74
669.50
725.16
648.59
546.75
956.59
1,323.66
% Of Sales
-
6.88%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
General & Admin Exp.
-
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
253.29
% Of Sales
-
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
Selling & Distn. Exp.
-
1,092.27
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
% Of Sales
-
9.25%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
Miscellaneous Exp.
-
54.46
48.49
78.68
121.44
47.19
33.29
314.55
88.52
38.82
991.23
% Of Sales
-
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
EBITDA
2,351.38
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
EBITDA Margin
17.65%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
Other Income
113.72
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
20.00
6.88
Interest
207.06
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
178.88
190.15
Depreciation
486.01
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
234.28
300.41
PBT
1,399.20
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
Tax
352.08
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
300.94
334.07
Tax Rate
25.16%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
PAT
1,047.14
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
PAT before Minority Interest
1,047.10
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
Minority Interest
-0.04
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
PAT Margin
7.86%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
PAT Growth
157.19%
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
 
EPS
37.11
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29
26.34
7.43

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
27.13
Total Reserves
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
Non-Current Liabilities
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
Trade Payables
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
Other Current Liabilities
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
Short Term Borrowings
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
347.60
Short Term Provisions
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
134.03
216.78
Total Liabilities
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
Net Block
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
Gross Block
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
Accumulated Depreciation
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
Non Current Assets
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
Capital Work in Progress
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
Non Current Investment
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
17.20
17.12
Long Term Loans & Adv.
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
69.99
468.16
Other Non Current Assets
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
0.27
Current Assets
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
Sundry Debtors
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
Cash & Bank
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
Other Current Assets
1,397.16
316.61
297.46
671.05
1,147.78
1,312.40
1,391.61
1,273.61
986.77
774.38
Short Term Loans & Adv.
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
594.89
742.94
Net Current Assets
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
Total Assets
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
PBT
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
Adjustment
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
522.76
Changes in Working Capital
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
Cash after chg. in Working capital
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
Net Fixed Assets
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
Net Investments
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
Others
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
Cash from Financing Activity
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
Net Cash Inflow / Outflow
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
Opening Cash & Equivalents
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
Closing Cash & Equivalent
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
65.74
ROA
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
ROE
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
ROCE
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
Fixed Asset Turnover
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
1.96
1.90
Receivable days
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
119.39
125.97
Inventory Days
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
67.68
59.42
Payable days
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
117.03
95.22
Cash Conversion Cycle
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
90.17
Total Debt/Equity
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
2.13
Interest Cover
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28
6.84
3.86

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Glenmark Pharmaceuticals launches TEVIMBRA in India
    24th Jun 2025, 12:30 PM

    This launch marks Glenmark’s first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio

    Read More
  • USFDA concludes GMP inspection at Glenmark Pharmaceuticals’ USA manufacturing facility
    18th Jun 2025, 10:37 AM

    At the end of the inspection, the Company was issued a Form 483 with five observations

    Read More
  • Glenmark Pharmaceuticals to launch zanubrutinib in India
    9th Jun 2025, 12:00 PM

    Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA

    Read More
  • Glenmark Pharmaceuticals reports consolidated net profit of Rs 4.38 crore in Q4
    26th May 2025, 12:20 PM

    The total consolidated income of the company decreased by 14.81% at Rs 3,267.89 crore for Q4FY25

    Read More
  • Glenmark Pharmaceuticals’ arm to launch generic Adderall tablets
    17th Apr 2025, 12:21 PM

    The company will begin distribution in May 2025

    Read More
  • Glenmark Pharmaceuticals’ arm recalls over 25 products in US market
    14th Apr 2025, 11:16 AM

    It is also recalling products like Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets and Rufinamide Tablets

    Read More
  • Glenmark’s US arm recalling 8,160 bottles of chlorpromazine hydrochloride tablets in US
    11th Apr 2025, 15:08 PM

    The company initiated the Class II nationwide (US) recall on March 11, 2025

    Read More
  • Glenmark’s US arm launches Vancomycin Hydrochloride for injection USP
    1st Apr 2025, 10:07 AM

    The Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of around $39.3 million

    Read More
  • Glenmark’s US arm gets USFDA’s approval for Olopatadine Hydrochloride Ophthalmic Solution
    21st Mar 2025, 09:35 AM

    Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.